Drug

Valsartan

In clinical development

ClassType-1 angiotensin II receptor antagonistEmerging researchLate-stage developmentSteady momentum

Also known as Byvalson, Diovan, Diovan HCT, Entresto+7 more

Byvalson, Diovan, Diovan HCT, Entresto, Exforge, Exforge HCT, N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, Valturna, Hydrochlorothiazide-Valsartan, Sacubitril-Valsartan, Amlodipine/Hydrochlorothiazide/Valsartan.

RxNorm69749 ChEMBLCHEMBL1069 ATCC09CA03UNII80M03YXJ7I

Research papers

Active clinical trials

Type-1 angiotensin II receptor

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Double-Blind, Randomized, Active-Controlled Phase 2a Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TriGlytza®-01 in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy

Clinical trial2026-07-08Results expected Q3 2027 · ClinicalTrials.gov

Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)

Clinical trial2026-07-08Results expected Q4 2028 · ClinicalTrials.gov

Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition

Clinical trial2026-06-30Suspended · ClinicalTrials.gov

Effects of VALsartan On atRIAl Mitral Regurgitation: A Pilot Randomized Controlled Trial

Clinical trial2026-05-12Results expected Q2 2029 · ClinicalTrials.gov

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

Clinical trial2026-05-09Completed · ClinicalTrials.gov

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Clinical trial2026-05-08Results expected Q1 2029 · ClinicalTrials.gov

Repurposing Valsartan May Protect Against Pulmonary Hypertension

Clinical trial2026-05-04Results expected Q3 2027 · ClinicalTrials.gov

Natriuretic Peptide-Renin-Angiotensin-Aldosterone System Rhythm Axis and Nocturnal Blood Pressure

Clinical trial2026-04-09Results expected Q1 2027 · ClinicalTrials.gov

Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.

Research2024-06-26European journal of heart failure

Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination.

Research2015-03-28Journal of the American Society of Hypertension : JASH

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Research2014-08-30The New England journal of medicine

Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.

Research2013-05-01Journal of hypertension

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Valsartan

Aliases & brands

ByvalsonDiovanDiovan HCTEntrestoExforgeExforge HCTN-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valineValturnaHydrochlorothiazide-ValsartanSacubitril-ValsartanAmlodipine/Hydrochlorothiazide/Valsartan

RxNorm CUI

69749

ChEMBL ID

CHEMBL1069

ATC codes

C09CA03

UNII

80M03YXJ7I

Primary mechanism

Type-1 angiotensin II receptor antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Type-1 angiotensin II receptor

AGTR1 · P30556

ANTAGONISTType-1 angiotensin II receptor antagonist

Clinical trials

190 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

190

registered trials across all phases

LATEST COMPLETION 2026

Active studies

Recruiting

151

Late-stage (III+)

128

Completed

Discontinued

PHASE DISTRIBUTIONn = 190

Early Phase 11Phase 116Phase 1 / 21Phase 221Phase 2 / 34Phase 348Phase 483Phase N / A16

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Pilot Randomized Clinical Trial to Assess Feasibility, Safety, and Efficacy of Rapid, Simultaneous Therapy Initiation in Chronic Kidney Disease and Type 2 Diabetes: RAPID-CKD

Not yet recruitingPH IVBaylor Research Instituten=642029

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent

RecruitingPH IVSilesian Centre for Heart Diseasesn=6002029

The Role of the Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose Metabolism Among African Americans: Pilot Study

Active, not recruitingPH IVOhio State Universityn=902026

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

CompletedPH IVZiekenhuis Oost-Limburgn=842026

Huaiqihuang Granules in the Treatment of Primary Glomerulonephritis of Stage CKD3: a Randomized, Double-blind, Double-simulation, Positive Parallel Control Multi-center Clinical Study

Unknown statusPH IVThe First Affiliated Hospital of Dalian Medical Universityn=4662026

Recent completions

Trials that read out recently, adding to the completed evidence base.

Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation

CompletedPH IVZiekenhuis Oost-Limburgn=842026

Clinical Study Evaluating Efficacy and Safety Sacubitril-valsartan in Patients With Heart Failure.

CompletedN/ADamanhour Universityn=602026

Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation

CompletedPH IVShanghai Jiao Tong University School of Medicinen=3202026

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

CompletedPH IIBrigham and Women's Hospitaln=452026

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

CompletedPH IIMostafa Bahaan=602025

Initiation of Angiotensin Receptor-neprilysin Inhibitor (ARNi) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): the INITIATE-HFrEF Randomized Open-label Trial

CompletedPH IVUniversidade do Porton=622025

Research activity

6 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20032024

Most influential

Angiotensin-neprilysin inhibition versus enalapril in heart failure.

The New England journal of medicine · 2014 · 4,715 cites

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

The New England journal of medicine · 2003 · 1,589 cites

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.

The New England journal of medicine · 2004 · 1,345 cites

Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: Cardiac structure and function, clinical outcomes, and response to sacubitril/valsartan in PARAGON-HF.

European journal of heart failure · 2024 · 19 cites

Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination.

Journal of the American Society of Hypertension : JASH · 2015 · 12 cites

Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.

Journal of hypertension · 2013 · 10 cites

Related diseases

3 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Heart Failure3 Cardiovascular Diseases2 Myocardial Infarction2

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Captopril

Studied across 6 of the same disease areas as Valsartan in the shared literature.

6 shared diseases2 shared papers

Valine

Studied across 6 of the same disease areas as Valsartan in the shared literature.

6 shared diseases2 shared papers

Enalapril

Studied across the same disease area as Valsartan in the shared literature.

1 shared disease1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials